For the first time in the mental health industry, Sentio Solutions has used objective data collected from physiological signals detected by their proprietary Feel Emotion Sensor, an emotion tracking wearable device, to understand and quantify the changes to the emotional states of a sample group of participants in Europe and the USA, the company said.
Results from this recent study showed sudden and significant changes to those physiological signals, indicating that emotional changes or new emotions were being experienced.
Over the course of eight weeks, between February 2020 and April 2020, Sentio collected data from a random sample group of participants in Europe and the USA, and analyzed 128 million electro-dermal activity (EDA) samples, 400 million heart rate variability (HRV) samples, 64 million skin temperature (ST) samples, and approximately 900 significant emotional moments.
Sentio Solutions is a San Francisco based company, which develops biomarkers and digital therapeutics to change the way we diagnose, manage and care for mental health. The company´s premier offering Feel, combines its proprietary Feel Emotion Sensor with Cognitive Behavioral Therapy (CBT) in order to bring a data-driven approach to the field of mental health for the very first time, while providing real-time interventions and care to those in need of emotional and mental health support. Sentio Solutions is backed by top VC firms and has kicked-off deployments with large Health & Life insurers in the USA and Germany. Feel is involved in many active research projects in collaboration with universities.